RGD Reference Report - Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Authors: Wang, Li-E  Ma, Hongxia  Hale, Katherine S  Yin, Ming  Meyer, Larissa A  Liu, Hongliang  Li, Jie  Lu, Karen H  Hennessy, Bryan T  Li, Xuesong  Spitz, Margaret R  Wei, Qingyi  Mills, Gordon B 
Citation: Wang LE, etal., J Cancer Res Clin Oncol. 2012 Mar;138(3):377-85. doi: 10.1007/s00432-011-1103-0. Epub 2011 Dec 7.
RGD ID: 13432140
Pubmed: PMID:22146979   (View Abstract at PubMed)
PMCID: PMC3526101   (View Article at PubMed Central)
DOI: DOI:10.1007/s00432-011-1103-0   (Journal Full-text)


PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mTOR and Ras/Raf/MEK/ERK pathways have been implicated in endometrial tumorigenesis. In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer.
METHODS: We genotyped a total of 48 potentially functional SNPs in 11 key genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) with the Sequenom genotyping platform in 115 endometrial cancer patients and 230 cancer-free women to evaluate their associations with risk, survival, and recurrence of endometrial cancer.
RESULTS: We found the following: (1) PIK3CA rs6443624 and rs9838411 variants either borderline or significantly decreased risk of endometrial cancer in a dominant model (adjusted odds ratio [OR], 0.62; 95% CI, 0.39-1.00 and 0.59; 95% CI, 0.36-0.95, respectively). Furthermore, there was a statistically significant multiplicative interaction (P (int) = 0.036) between these two loci in risk of endometrial cancer. In contrast, the AKT1 rs2498801 genotype significantly increased risk of endometrial cancer (adjusted OR, 1.94; 95% CI, 1.02-3.67 in a recessive model). (2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients. (3) KRAS rs7312175 and PIK3CA rs6443624 had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003).
CONCLUSION: These results suggest that common genetic variations in these pathways may modulate risk and clinical outcomes of endometrial cancer. Further replication and functional studies are needed to confirm these findings.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
endometrial cancer severityIAGP 13432140DNA:snp:intron:c.287+993G>A (rs892119) (human)RGD 
endometrial cancer severityISOAKT2 (Homo sapiens)13432140; 13432140DNA:snp:intron:c.287+993G>A (rs892119) (human)RGD 

Molecular Pathway Annotations    Click to see Annotation Detail View

RGD Manual Annotations

TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
endometrial cancer pathway  severityIMP 13432140 RGD 
endometrial cancer pathway  severityISOAKT2 (Homo sapiens)13432140; 13432140 RGD 
Objects Annotated

Genes (Rattus norvegicus)
Akt2  (AKT serine/threonine kinase 2)

Genes (Mus musculus)
Akt2  (thymoma viral proto-oncogene 2)

Genes (Homo sapiens)
AKT2  (AKT serine/threonine kinase 2)


Additional Information